FDA Drug recall D-0725-2022
Avaphinal Maximum Male Enhancement Sexual Pills, 2000 MG*, packaged in 10 Capsules per carton
- FDA Drug
- Class I
- terminated
- Published 2022-03-23
On 2022-03-23 the FDA classified a Class I recall of Avaphinal Maximum Male Enhancement Sexual Pills, 2000 MG*, packaged in 10 Capsules per carton by Walmart Stores, citing marketed Without An Approved NDA/ANDA: Product was found to contain undeclared sildenafil, an ingredient found in FDA approved products for the treatment of male sexual enhancemen….
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0725-2022 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2022-02-09 |
| Published | 2022-03-23 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Walmart Stores |
| Distribution | US |
Product
Avaphinal Maximum Male Enhancement Sexual Pills, 2000 MG*, packaged in 10 Capsules per carton.
Reason
Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared sildenafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Identifiers
| code_info | Lot: DK1027, Exp 08/01/2023 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0725-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.